Sef Regulates Epithelial-Mesenchymal Transition in Breast Cancer Cells

Journal of Cellular Biochemistry

Volumn , Issue , 2016, Pages 2346-2356

  He, Qing ^a,b   Gong, Yan ^a,b   Gower, Lindsey ^a   Yang, Xuehui ^a   Friesel, Robert E ^a,b  

^a Maine Medical Center Research Institute   (United States)

^b UNIVERSITY OF MAINE   (United States)

Author keywords

BREAST CANCER; EPITHELIAL MESENCHYMAL TRANSITION; MIGRATION; SEF; SLUG; SNAIL

Indexed keywords

BETA CATENIN; LUCIFERASE; MEMBRANE PROTEIN; PROTEIN SEF; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; GENE EXPRESSION; IMMUNOPRECIPITATION; MCF 7 CELL LINE; MCF10A CELL LINE; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

EID: 84984973468     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25532     Document Type: Article

References (22)

1. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, Taya Y. 2008. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 68:5104–5112.
2. Cabrita MA, Christofori G. 2008. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 11:53–62.
3. Darby S, Murphy T, Thomas H, Robson CN, Leung HY, Mathers ME, Gnanapragasam VJ. 2009. Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. Br J Cancer 101:1891–1899.
4. Darby S, Sahadevan K, Khan MM, Robson CN, Leung HY, Gnanapragasam VJ. 2006. Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene 25:4122–4127.
5. Dikic I, Giordano S. 2003. Negative receptor signalling. Curr Opin Cell Biol 15:128–135.
6. Friesel RE, Maciag T. 1995. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J 9:919–925.
7. Furthauer M, Lin W, Ang SL, Thisse B, Thisse C. 2002. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol 4:170–174.
8. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428.
9. Korc M, Friesel RE. 2009. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 9:639–651.
10. Kovalenko D, Yang X, Chen PY, Nadeau RJ, Zubanova O, Pigeon K, Friesel R. 2006. A role for extracellular and transmembrane domains of Sef in Sef-mediated inhibition of FGF signaling. Cell Signal 18:1958–1966.
11. Kovalenko D, Yang X, Nadeau RJ, Harkins LK, Friesel R. 2003. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 278:14087–14091.
12. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134.
13. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790.
14. Preger E, Ziv I, Shabtay A, Sher I, Tsang M, Dawid IB, Altuvia Y, Ron D. 2004. Alternative splicing generates an isoform of the human Sef gene with altered subcellular localization and specificity. Proc Natl Acad Sci USA 101:1229–1234.
15. Thisse B, Thisse C. 2005. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 287:390–402.
16. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. 2004. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 7:33–44.
17. Tsang M, Friesel R, Kudoh T, Dawid IB. 2002. Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 4:165–169.
18. Yang RB, Ng CK, Wasserman SM, Komuves LG, Gerritsen ME, Topper JN. 2003. A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. J Biol Chem 278:33232–33238.
19. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. 1996. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10:1443–1454.
20. Zhang H, Zhao X, Yan L, Li M. 2011. Similar expression to FGF (Sef) reduces endometrial adenocarcinoma cells proliferation via inhibiting fibroblast growth factor 2-mediated MAPK/ERK signaling pathway. Gynecol Oncol 122:669–674.
21. Zisman-Rozen S, Fink D, Ben-Izhak O, Fuchs Y, Brodski A, Kraus MH, Bejar J, Ron D. 2007. Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas. Oncogene 26:6093–6098.
22. Ziv I, Fuchs Y, Preger E, Shabtay A, Harduf H, Zilpa T, Dym N, Ron D. 2006. The human Sef-a isoform utilizes different mechanisms to regulate FGFR signaling pathways and subsequent cell fate. J Biol Chem 281:39225–39235.